Welcome, Guest. Please login or register.
July 15, 2024, 02:27:28 pm

Login with username, password and session length

  • Total Posts: 55130
  • Total Topics: 4851
  • Online Today: 209
  • Online Ever: 1314
  • (June 22, 2016, 05:23:42 am)
Users Online
Users: 0
Guests: 30
Total: 30


Welcome to the Hep Forums, a round-the-clock discussion area for people who have Fatty Liver Disease, Hepatitis B, C or a co-infection, their friends and family and others with questions about hepatitis and liver health. Check in frequently to read what others have to say, post your comments, and hopefully learn more about how you can reach your own health goals.

Privacy Warning: Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.
  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.
  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.
  • Product advertisement (including links); banners; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from the Hep Forum Moderators.
Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: 6% of Medicare Recipients Receiving Hep C Treatment Discontinue Early  (Read 7340 times)

0 Members and 1 Guest are viewing this topic.

Offline Hep Editors

  • Member
  • Posts: 784
    • Hep Mag
Among people whose direct-acting antiviral (DAA) treatment for hepatitis C virus (HCV) is covered by Medicare, 6% discontinued therapy early between 2014 and 2016. This figure, while low, is still three times greater than the rate seen in clinical trials, and it was higher depending on individual characteristics of the people undergoing treatment for the virus, including which regimen they took and whether they had cirrhosis.

Thomas Riley III, MD, of Penn State, and colleagues conducted an analysis of 82,056 people on Medicare who started DAA treatment for HCV between January 2014 and September 2016. They defined treatment discontinuation as filling prescriptions for fewer weeks than expected for their prescribed DAA regimen. Their findings were published in the American Journal of Managed Care.



© 2024 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.